[topsearch__bar__shortcode]

September 18, 2020

BASE Stock

Two Reasons Why ClearOne Inc [CLRO] is a Perfect Buy at Current Prices

ClearOne Inc [NASDAQ:CLRO] has over the last few days 0recovered most of the losses from late August and the better part September. From a technical analysis perspective, the stock is at a price level where it can go in any direction. Ideally, the best entry point for this stock would be any price level above […]

Two Reasons Why ClearOne Inc [CLRO] is a Perfect Buy at Current Prices Read More »

AIM ImmunoTech

Here’s Why You Should Avoid iBio (IBIO) Stocks For COVID-19 Vaccine

All the companies involved in the production of the coronavirus vaccine, iBio is far behind from its competitors in the vaccine trial. The company has earlier revealed that it has selected IBIO-201, its LicKM-ubunit vaccine, as its leading candidate for the prevention of coronavirus infection. But the company has not provided any promising result related

Here’s Why You Should Avoid iBio (IBIO) Stocks For COVID-19 Vaccine Read More »

BRQS Stock

10 Trending Stocks In Business Equipment And Supplies Industry

The growing trends of the fourth industrial revolution have changed the way we work and how we engage with our customers. The Business Supplies and Equipment Industry comprised of companies that make a variety of products for a diverse customer base. The business supplies industry is engaged in the manufacturing and selling of integrated furniture

10 Trending Stocks In Business Equipment And Supplies Industry Read More »

WonderFi

Cardiff (NASDAQ: CRDF) Confirms Efficacy Of Onvansertib In Colorectal Cancer

Shares of Cardiff Oncology, Inc. (NASDAQ: CRDF) were traded up 39.59% after it announced that Onvansertib has shown the clinical benefit in colorectal cancer. The company has presented data of Ovansertib at the European Society of Medical Oncology Virtual Congress. Cardiff Oncology is currently engaged in the Phase 1b/2clinical trial of Ovansertib Metastatic KRAS-mutated Colorectal

Cardiff (NASDAQ: CRDF) Confirms Efficacy Of Onvansertib In Colorectal Cancer Read More »